First-in Human Implantation of a Novel Biologic Valved Conduit for Aortic Root Replacement

Abstract Aortic root replacement is a complex procedure. Recently, the Konect Resilia aortic valved conduit® (Edwards Lifesciences), the first prefabricated biologic valved conduit available in the United States of America, was approved for use. Here we report the initial series of three patients representing the first-in-human implantation of the novel Konect biobentall. The conduit was implanted in both supra-annular and intra-annular positions, and the unique design of the sewing ring offers several advantages. The Konect biobentall streamlines the process of root replacement and may represent an improvement in terms of ease-of-implantation and durability.